Description of the Method for Evaluating Digital Endpoints in Alzheimer Disease Study: Protocol for an Exploratory, Cross-sectional Study

BACKGROUND: More sensitive and less burdensome efficacy end points are urgently needed to improve the effectiveness of clinical drug development for Alzheimer disease (AD). Although conventional end points lack sensitivity, digital technologies hold promise for amplifying the detection of treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Curcic, Jelena, Vallejo, Vanessa, Sorinas, Jennifer, Sverdlov, Oleksandr, Praestgaard, Jens, Piksa, Mateusz, Deurinck, Mark, Erdemli, Gul, Bügler, Maximilian, Tarnanas, Ioannis, Taptiklis, Nick, Cormack, Francesca, Anker, Rebekka, Massé, Fabien, Souillard-Mandar, William, Intrator, Nathan, Molcho, Lior, Madero, Erica, Bott, Nicholas, Chambers, Mieko, Tamory, Josef, Shulz, Matias, Fernandez, Gerardo, Simpson, William, Robin, Jessica, Snædal, Jón G, Cha, Jang-Ho, Hannesdottir, Kristin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2022
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403829/
https://www.ncbi.nlm.nih.gov/pubmed/35947423
http://dx.doi.org/10.2196/35442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403829/
https://www.ncbi.nlm.nih.gov/pubmed/35947423
http://dx.doi.org/10.2196/35442

Ejemplares similares